Three Phase III wins in a single August, across three distinct tumor types, is not a pipeline story anymore — it is a clinical infrastructure story. Akeso’s ivonescimab, a PD-1/VEGF bispecific antibody, posted an overall survival hazard ratio of 0.76 in EGFR-TKI-resistant NSCLC (with Western patients matching the China cohort almost exactly at HR 0.76 versus 0.74), beat durvalumab-based chemotherapy on OS in first-line biliary tract cancer, and received NMPA approval for squamous NSCLC on the back of dual positive OS and PFS data versus a PD-1 monoclonal antibody plus chemotherapy in a randomized, double-blind Phase III — a bar that comparator arms built around pembrolizumab, approved for first-line PD-L1-positive NSCLC since 2016, had not previously crossed in a head-to-head setting.
The commercial read is just as important as the clinical one. First-half 2026 drug sales hit RMB 1,803.2 million, up 28.7% year-over-year, with all 12 approved indications now inside China’s National Reimbursement Drug List. That reimbursement sweep matters because NRDL inclusion is what converts Phase III wins into volume, and Akeso is sitting on RMB 9,160 million in cash to fund what comes next. The FDA BLA for ivonescimab in EGFR-TKI-resistant NSCLC is already under review, making the HR 0.76 OS data the number regulators are now evaluating against a setting where approved checkpoint options carry EGFR/ALK resistance restrictions and sequential therapy after TKI failure remains genuinely difficult to optimize.
The strategic depth behind these readouts is what separates this from a routine interim update. Ivonescimab is running in more than 17 registrational Phase II/III studies, including seven global trials and eight using standard-of-care active comparators. Cadonilimab, the PD-1/CTLA-4 bispecific, is enrolled in more than 13 registrational or Phase III studies and is being tested against nivolumab-based chemotherapy in gastric cancer — a direct challenge to an entrenched first-line combination. Partnership trials span Revolution Medicines, ARCUS Biosciences, and collaborations with Dana-Farber and Mass General Brigham, meaning the combination data generating over the next 18 months will come from externally validated academic sites, not only Akeso-controlled studies.
The single marker to track now is the FDA’s action on the EGFR-TKI-resistant NSCLC BLA. A U.S. approval would transform ivonescimab from a China-dominant commercial asset into a global one, and the consistency between the Western-patient HR (0.76) and the China-conducted HARMONi-A result (HR 0.74) removes the usual concern about ethnic subgroup heterogeneity that slows cross-border extrapolation. That decision date is the one clinical calendar event that changes the scale of this story.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
